RecruitingPhase 2NCT07749716

Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Severe Alopecia Areata

Sponsor

Jiangsu vcare pharmaceutical technology co., LTD

Enrollment

120 participants

Start Date

Aug 18, 2026

Study Type

INTERVENTIONAL

Conditions

Alopecia Areata

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of VC005 tablets in subjects with severe alopecia areata (AA).

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Drug: VC005 tablets, a drug called VC005 placebo tablets, and others for people with alopecia areata. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.